PPARγ配体罗格列酮及其激动剂GW9662 对脂肪细胞因子表达的影响

摘要/Abstract

摘要： 目的: 脂肪组织是一个内分泌器官已逐渐得到了肯定, 它能分泌多种信号分子如:脂联素和抵抗素。过氧化物酶体增殖物激活受体(peroxisome proliferatoractivated receptor γ, PPARγ)在脂肪组织高水平表达, 胰岛素增敏剂-噻唑烷二酮类药物是它的选择性激动剂, 噻唑烷二酮类药物如罗格列酮的胰岛素增敏作用部分是通过激活PPARγ调节脂联素(胰岛素增敏分子)和抵抗素(涉及胰岛素抵抗)表达介导的。但现在不同研究发现PPARγ激动剂对抵抗素的表达调控方向存在矛盾, 我们的问题是当抵抗素表达增加的情况下脂联素的表达还能否上调。方法: 用3T3-L1 细胞株作为研究模型, 分别用溶媒对照、罗格列酮(10 μmol/L)、GW9662(5 μmol/L)或罗格列酮+GW9662 作用细胞, 然后检测脂联素和抵抗素mRNA 表达变化情况。结果: 与对照组相比, 罗格列酮分别增加脂联素和抵抗素mRNA 水平1. 77和1. 66 倍, 其差异具有统计学意义(P<0.05);重要的是GW9662 也增加脂联素水平(1. 57 倍, P<0.05)但对抵抗素无影响。罗格列酮和GW9662 两者合用时, 仍上调adiponectin mRNA 水平(对照组的1. 87 倍, P<0.05), 抵抗素的增加与罗格列酮单用比弱下降(对照组的1. 31 倍, P<0.05)。结论: 本研究为PPARγ 激动剂(罗格列酮)和拮抗剂(GW9662)都上调脂联素的转录提供了新的证据, 两者合用时GW9662 不阻断罗格列酮诱导的脂联素上调作用。综合这些数据提示噻唑烷二酮类药上调脂联素的机制可能不依赖于PPARγ。并且, GW9662在增加脂联素水平的同时不上调抵抗素水平的特性进一步支持PPARγ拮抗剂用于临床治疗胰岛素抵抗的可能性。降低抵抗素表达可能不是罗格列酮胰岛素增敏作用的重要机制。我们的结果为将来研究噻唑烷二酮类药物对人脂肪细胞因子表达在剂量和时间上提供了一定的基础。

关键词: 过氧化物酶体增殖物激活受体, 罗格列酮, GW9662, 脂联素, 抵抗素

Abstract: BACKGROUND: There is a growing recognition that the adipose tissue is an endocrine organ that secretes signaling molecules such as adiponectin and resistin.The peroxisome proliferator activated receptor γ (PPARγ)is expressed in high levels in the adipose tissue.Thiazolidinediones are selective PPARγagonists with insulin-sensitizing properties.It has been postulated that thiazolidinediones such as rosiglitazone exert their pharmacodynamic effects in part through modulation of resistin (implicated in insulin resistance)and adiponectin (an insulin- sensitizing molecule)expression subsequent to activation of PPARγ.There are conflicting data, however, on the biological direction in which resistin expression is modulated by PPARγagonists and whether an increase in adiponectin expression can occur in the face of an upregulation of resistin. METHODS: Using the murine 3T3-L1 adipocytes as a model, we evaluated the changes in resistin and adiponectin gene expression after vehicle, rosiglitazone (10 μmol/L, a PPARγagonist), GW9662 (5 μmol/L, a selective PPARγantagonist)or GW662 and rosiglitazone co-treatment. RESULTS: In comparison to vehicle treatment, rosiglitazone increased the average adiponectin and resistin mRNA expression by 1.66- and 1.55-fold, respectively (P<0.05).Importantly, GW9662 also upregulated adiponectin expression (by 1.57-fold, P<0.05)but did not influence resistin expression (P> 0.05).Co-treatment with rosiglitazone and GW9662 maintained the adiponectin upregulation (1.87-fold increase from vehicle, P<0.05)while attenuating resistin upregulation (1.31-fold increase from vehicle, P<0.05)induced by rosiglitazone alone (1.55-fold increase from vehicle, P<0.05). CONCLUSION: This study presents new evidence that adiponectin transcript is upregulated with both a PPARγagonist (rosiglitazone)and antagonist (GW9662), while GW9662 co-treatment does not block rosiglitazone-induced adiponectin upregulation.These data collectively suggest that biological mechanisms independent from PPARγmay underlie thiazolidinedione pharmacodynamics on adiponectin expression.Moreover, increased adiponectin expression by GW9662, in the absence of an upregulation of resistin expression, lends further support on the emerging clinical potential of PPARγ antagonists in treatment of insulin resistance.Decreased resistin expression may not be crucial for the insulin-sensitizing effect of rosiglitazone.These findings may serve as a foundation for future dose-ranging and time-course studies of thiazolidinedione pharmacodynamics on adipocytokine expression in human adipocytes.

Key words: PPARγ, obesity, diabetes, insulin resistance, GW9662, thiazolidinediones, rosiglitazone, adipocytokine, 3T3-L1 adipocytes, gene expression

. PPARγ配体罗格列酮及其激动剂GW9662 对脂肪细胞因子表达的影响[J]. 中国临床药理学与治疗学, 2007, 12(10): 1157-1162.

LIU Ying-zi, Vural Ozdemir, OUYANG Dong-sheng, LIU Zhao-qian, LIU ie, LI Zhi,WANG Dan, ZENG Fei-yue, TAN Zhi-rong, HU Dong-li, ZHOU Hong-hao. Differential effects of PPARγligand rosiglitazone and selective antagonist GW9662 on adipocytokine gene expression in 3T3-L1 adipocytes[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2007, 12(10): 1157-1162.

参考文献

1 Matsuzawa Y.The metabolic syndrome and adipocytokines[J]. FEBS Lett, 2006;580:2917-2921.
2 Desvergne B, Wahli W.Peroxisome proliferator-activated receptors: nuclear control of metabolism[J].Endocr Rev, 1999; 20:649-688.
3 Steppan CM, Bailey ST, Bhat S, et al. The hormone resistin links obesity to diatetes[J].Nature, 2001;409:307-312.
4 Maeda N, Takahashi M, Funahashi T, et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein[J].Diabetes, 2001;50:2094-2099.
5 Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects[J].Diabetes, 2002;51:2968-2974.
6 Hirose H, Kawai T, Yamamoto Y, et al. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with Type 2 diabetes [J].Metabolism, 2002;51:314-317.
7 Haluzik MM, Lacinova Z, Dolinkova M, et al. Improvement of insulin sensitivity after peroxisome proliferator-activated receptoralpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels[J].Endocrinology, 2006;147:4517-4524.
8 Kim KH, Lee K, Moon YS, et al. A cysteine-rich adipose tissue-specific secretory factor inhibits adipocyte differentiation[J]. J Biol Chem, 2001;276:11252-11256.
9 Way JM, Gorgun CZ, Tong Q, et al. Adipose tissue resistin expression is severely suppressed in obesity and stimulated by peroxisome proliferator-activated receptor gamma agonists[J].J Biol Chem, 2001;276:25651-25653.
10 Doggrell S.Do peroxisome proliferation receptor-gamma antagonists have clinical potential as combined antiobesity and antidiabetic drugs[J] ? Expert Opin Investig Drugs, 2003;12:713-716.
11 Ahluwalia M, Evans M, Morris K, et al. The influence of the Pro12Ala mutation of the PPAR-gamma receptor gene on metabolic and clinical characteristics in treatment-naive patients with type 2 diabetes[J].Diabetes ObesMetab, 2002;4:376-378.
12 StumvollM, Wahl HG, Loblein K, et al. Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with increased antilipolytic insulin sensitivity[J]. Diabetes, 2001;50:876-881.
13 Kubota N, Terauchi Y, Miki H, et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance[J].Mol Cell, 1999;4:597-609.
14 Rieusset J, Touri F, Michalik L, et al. A new selective peroxisome proliferator-activated receptor γantagonist with antiobesity and antidiabetic activity[J].Mol Endocrinol, 2002;16:2628-2644.
15 Mukherjee R, Hoener PA, Jow L, et al. A selective peroxisome proliferator-activated receptor-gamma (PPARgamma) modulator blocks adipocyte differentiation but stimulates glucose uptake in 3T3-L1 adipocytes[J].Mol Endocrinol, 2000;14: 1425-1433.
16 Liu Y, Zhang Y, Schmelzer K, et al. The antiinflammatory effect of laminar flow:the role of PPARgamma, epoxyeicosatrienoic acids, and soluble epoxide hydrolase[J].Proc Natl Acad Sci USA, 2005;102:16747-16752.
17 Nakano R, Kurosaki E, Yoshida S, et al. Antagonism of peroxisome proliferator-activated receptor gamma prevents high-fat diet-induced obesity in vivo[J].Biochem Pharmacol, 2006; 72:42-52.
18 Ling C, Kindblom J, Wennbo H, et al. Increased resistin expression in the adipose tissue of male prolactin transgenic mice and in male mice with elevated androgen levels[J].FEBS Lett, 2001;507:147-150.
19 Fasshauer M, Klein J, Neumann S, et al. Adiponectin gene expression is inhibited by beta-adrenergic stimulation via protein kinase A in 3T3-L1 adipocytes[J].FEBS Lett, 2001;507:142-146.
20 Mori Y, Murakawa Y, Okada K, et al. Effect of troglitazone on body fat distribution in Type 2 diabetic patients[J].Diabetes Care, 1999;22:908-912. 21 Ozdemir V, Williams-Jones B, Cooper DM, et al. Mapping translational research in personalized therapeutics:From molecular markers to health policy[J].Pharmacogenomics, 2007;in press. 22 Lazar MA.PPAR gamma, 10 years later [J].Biochimie, 2005;87:9-13.

[1]	王安婧, 王亚亚, 梁轩, 闫雅婕, 苏静, 李彩东. 基于PPAR治疗胆汁淤积性肝病的机制与药物研究进展[J]. 中国临床药理学与治疗学, 2023, 28(7): 796-808.
[2]	郭怡洵, 关晓印, 王博, 魏英达, 张岩, 林建华. 肌少性肥胖的发病机制及潜在治疗靶点研究进展[J]. 中国临床药理学与治疗学, 2023, 28(3): 341-346.
[3]	王春玲, 周仁精, 冯瑞, 吴燕能. 脂联素45 T/G基因多态性对利拉鲁肽治疗2型糖尿病患者的临床疗效[J]. 中国临床药理学与治疗学, 2021, 26(3): 312-317.
[4]	范志鹏，李玲，赵慧佳，陈彬尧，刘晓红，郝卓文，孙功鹏，董礼，乐江，吴建国，叶啟发. PGC-1α基因多态性与代谢性疾病的相关性[J]. 中国临床药理学与治疗学, 2019, 24(10): 1172-1180.
[5]	谢珍，康桦，何立成，匡荣. 深海鱼油对高脂血症模型大鼠血脂的影响及机制探讨[J]. 中国临床药理学与治疗学, 2017, 22(8): 870-874.
[6]	张固琴, 杨炯. 罗格列酮对人肥大细胞株HMC-1细胞迁移的影响及机制研究[J]. 中国临床药理学与治疗学, 2015, 20(9): 981-984.
[7]	陆永娟, 陈芝芸, 严茂祥, 何蓓晖, 朱丹. 阿托伐他汀对非酒精性脂肪性肝病大鼠脂肪细胞因子的影响[J]. 中国临床药理学与治疗学, 2015, 20(5): 520-524.
[8]	周四桂, 徐立朋, 路遥, 袁茜, 潘雪刁, 臧林泉. 非诺贝特通过上调短链酰基辅酶A脱氢酶抑制大鼠心肌肥厚[J]. 中国临床药理学与治疗学, 2013, 18(8): 868-873.
[9]	黎小妍, 张平, 陶玲, 刘玉兴. 坎地沙坦对自发性高血压大鼠胰岛素抵抗及血清脂联素的影响[J]. 中国临床药理学与治疗学, 2013, 18(11): 1201-1204.
[10]	寿荣伟. 罗格列酮对2型糖尿病患者血脂及内脂素的影响[J]. 中国临床药理学与治疗学, 2013, 18(11): 1284-1287.
[11]	杨颖, 袁斌, 周春阳, 程龙献. 柚皮苷及柚皮素对高脂模型大鼠单核细胞过氧化物酶体增殖物激活受体-δ水平的影响[J]. 中国临床药理学与治疗学, 2013, 18(1): 6-10.
[12]	吴柯, 何百成, 周岐新. 罗格列酮对实验性大鼠结肠癌的化学预防作用[J]. 中国临床药理学与治疗学, 2012, 17(10): 1124-1129.
[13]	沈红燕, 吴晓冬. 黄芩苷对大鼠脂肪细胞胰岛素抵抗的改善作用[J]. 中国临床药理学与治疗学, 2011, 16(3): 263-269.
[14]	林佳, 刘广南, 潘竞锵, 邝少松, 黄小琼, 饶子亮. 溴隐停、罗格列酮和二甲双胍对改善多囊卵巢综合征(PCOS)大鼠胰岛素抵抗和下调促炎细胞因子及调血脂作用研究[J]. 中国临床药理学与治疗学, 2010, 15(4): 391-396.
[15]	孙红, 王少明, 庄捷, 刘海玲, 周宏灏, 刘昭前. 脂联素基因启动子-11377(C/G)基因多态性与中国2型糖尿病和罗格列酮降糖疗效的相关性研究[J]. 中国临床药理学与治疗学, 2010, 15(1): 82-88.